Continuous monitoring is reshaping oncology. CEO of AION Biosystems, Sam Barend, joins Dr. Sanjay Juneja, Dr. Douglas Flora, and Dr. David Penberthy to explore how long‑term physiologic tracking, AI‑driven insights, and clinically validated wearables are improving outcomes for patients at high risk of complications. The conversation highlights FDA pathways, reimbursement realities, and the promise of simpler, signal‑focused monitoring that detects patterns earlier and supports safer treatment continuity.
